Extended coverage expands access to iTind for BPH-related LUTS
iTind is a temporary nitinol device used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia.
Related Articles
Artificial intelligence in bladder cancer diagnostics
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
Anne Schuckman, MD, highlights promising new developments in NMIBC
Anne Schuckman, MD, on optimal sequencing strategies, the SWOG 1602 trial, and the emerging role of ctDNA.
Inside Men’s Health: A Clinician’s View
In this episode of AUA Inside Tract, join Dr. Petar Bajic, director of Men’s Health, and Dr. Raevti Bole, Men’s Health specialist, from the Cleveland…
Urologic Oncology: Adrenal, Renal, Ureteral, and Retroperitoneal Tumors | Journal of Urology
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
New EAU Endourology Fellowship Programme – Uroweb
Receive a scholarship grant and execute a year-long research project under the guidance of experts. Finetune your skills and enhance your knowledge in a leading…
June 2025 | European Urology Podcast
June 2025 brings another jam-packed edition of European Urology! Here on the European Urology Podcast we bring you selected highlights from the journal each …
Live Events
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
HF01-01 The “Exhibition of Living Patients”—Hutchinson, Ethics and Urology: Erratum | Journal of Urology
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
The phase 1 study is set to begin later this year.
Monogenic Lupus Nephritis Signals Earlier Onset and Worse Renal Outcomes – Renal and Urology News
A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease.
